Retrieve available abstracts of 8 articles: HTML format
Single Articles
September 2025
CHOON XY, Soh PJ, Hassan NA, Lim KS, et al Impact of Levetiracetam Cost on Epilepsy in a Resource-limited Country.
Clin Neuropharmacol. 2025 Sep 11. doi: 10.1097/WNF.0000000000000656. PubMedAbstract available
July 2025
DOPP LM, Jung J, Markert OL, Frazier DL, et al Postictal Psychosis, a Case Report.
Clin Neuropharmacol. 2025 Jul 10. doi: 10.1097/WNF.0000000000000644. PubMedAbstract available
RETTELE M, Conroy G, Barron A, Marut D, et al Hemodynamic Effects of Continuous Intravenous Midazolam in Refractory Status
Epilepticus.
Clin Neuropharmacol. 2025;48:112-117. PubMedAbstract available
May 2025
OMERHODZIC I, Rovcanin B, Dzurlic A, Hodzic M, et al Efficacy and Safety of Oxcarbazepine as Monotherapy for Prevention of Epileptic
Seizures in Patients With Supratentorial Brain Tumors: A Prospective Multicentric
Study.
Clin Neuropharmacol. 2025 May 9. doi: 10.1097/WNF.0000000000000639. PubMedAbstract available
KIM HK, Kwack DW, Kim DW Two-Year Retention Rate and Clinical Usefulness of Eslicarbazepine Acetate in
Epilepsy Patients.
Clin Neuropharmacol. 2025;48:93-96. PubMedAbstract available
ERTURK CETIN O, Algedik P, Akyuz G, Surmeli R, et al Minor/Major Congenital Malformations and Neurodevelopmental Outcomes in Children
Prenatally Exposed to Levetiracetam, Lamotrigine, and Carbamazepine Monotherapy.
Clin Neuropharmacol. 2025;48:61-66. PubMedAbstract available
February 2025
RALSTON MJ, Reed F, Osman A A Case of Post-Acute Severe Acute Respiratory Syndrome Coronavirus 2-Induced
Focal Nonconvulsive Status Epilepticus With Impairment of Consciousness Initially
Diagnosed as Anxiety.
Clin Neuropharmacol. 2025 Feb 5. doi: 10.1097/WNF.0000000000000621. PubMed
March 2024
TANTILLO G, Davis N, Granstein J, Yoo JY, et al Provider Experience With the Use of Ketamine for Refractory Status Epilepticus.
Clin Neuropharmacol. 2024;47:37-43. PubMedAbstract available